<p>擁有大量資金的投資者對 <strong>再生元製藥</strong> (NASDAQ: REGN) 持樂觀態度。</p>
<p>而散户交易者應該知道這一點。</p>
<p>我們今天注意到這一點，當交易出現在我們在 Benzinga 跟蹤的公開可用期權歷史中時。</p>
<p>無論這些是機構還是僅僅是富有的個人，我們都不知道。但當 REGN 發生如此重大的事情時，通常意味着有人知道即將發生什麼。</p>
<p>那麼我們如何知道這些投資者剛剛做了什麼呢？</p>
<p>今天，Benzinga 的期權掃描儀發現了 11 筆不尋常的再生元製藥期權交易。</p>
<p>這並不正常。</p>
<p>這些大資金交易者的整體情緒在 36% 看漲和 36% 看跌之間分裂。</p>
<p>在我們發現的所有特殊期權中，7 筆是看跌期權，總金額為 $344,526，4 筆是看漲期權，總金額為 $458,064。</p>
<h3>預測價格區間</h3>
<p>分析這些合約的成交量和未平倉合約，似乎大玩家在過去一個季度內關注再生元製藥的價格區間為 $400.0 到 $800.0。</p>
<h3>成交量與未平倉合約發展</h3>
<p>評估成交量和未平倉合約是期權交易中的一個戰略步驟。這些指標揭示了在指定行使價格下，投資者對再生元製藥期權的流動性和興趣。接下來的數據將可視化過去 30 天內與再生元製藥重大交易相關的看漲和看跌期權的成交量和未平倉合約的波動，行使價格範圍為 $400.0 到 $800.0。</p>
<h3>再生元製藥期權活動分析：過去 30 天</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768417244_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="期權看漲圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768417244_0.png"/></p>
<h3>發現的最大期權：</h3>
<table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行使價格</strong></th>
<th><strong>總交易價格</strong></th>
<th align="right"><strong>未平倉合約</strong></th>
<th align="right"><strong>成交量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$128.3</td>
<td>$122.4</td>
<td>$124.5</td>
<td>$630.00</td>
<td>$311.2K</td>
<td align="right">111</td>
<td align="right">25</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>掃描</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$15.5</td>
<td>$12.7</td>
<td>$15.5</td>
<td>$775.00</td>
<td>$65.1K</td>
<td align="right">346</td>
<td align="right">42</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>交易</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$15.2</td>
<td>$12.3</td>
<td>$15.2</td>
<td>$775.00</td>
<td>$63.8K</td>
<td align="right">346</td>
<td align="right">122</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>掃描</td>
<td>看漲</td>
<td>01/16/26</td>
<td>$17.4</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$775.00</td>
<td>$61.5K</td>
<td align="right">346</td>
<td align="right">302</td>
</tr>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>06/16/28</td>
<td>$185.0</td>
<td>$179.5</td>
<td>$185.0</td>
<td>$800.00</td>
<td>$55.5K</td>
<td align="right">4</td>
<td align="right">3</td>
</tr>
</tbody>
</table>
<h3>關於再生元製藥</h3>
<p>再生元製藥發現、開發和商業化用於治療眼病、心血管疾病、癌症和炎症的產品。該公司有多個已上市產品，包括用於濕性年齡相關性黃斑變性和其他眼病的低劑量 Eylea 和 Eylea HD；在免疫學領域的 Dupixent；用於降低 LDL 膽固醇的 Praluent；在腫瘤學領域的 Libtayo；以及在類風濕關節炎領域的 Kevzara。再生元還與賽諾菲及其他合作伙伴獨立開發單克隆抗體和雙特異性抗體，並與早期階段的合作伙伴關係引入新技術，包括 RNAi（Alnylam）和基於 Crispr 的基因編輯（Intellia）。</p>
<p>鑑於再生元製藥最近的期權歷史，現在適合關注該公司本身。我們旨在探討其當前表現。</p>
<h3>再生元製藥的當前市場狀況</h3>
<ul>
<li>目前交易量為 269,395，REGN 的價格上漲 0.21%，現為 $760.5。</li>
<li>RSI 指標顯示該股票目前在超買和超賣之間處於中性狀態。</li>
<li>預計盈利發佈將在 16 天內進行。</li>
</ul>
<h3>專家對再生元製藥的看法</h3>
<p>在過去一個月中，2 位專家對該股票發佈了評級，平均目標價格為 $840.0。</p>
<ul>
<li>一位來自美銀證券的分析師將其評級提升至買入，設定新的目標價格為 $860。</li>
<li>一位來自 Truist Securities 的分析師決定維持對再生元製藥的買入評級，目前目標價格為 $820。</li>
</ul>
<p>期權相比於僅交易股票是一種風險更高的資產，但它們具有更高的利潤潛力。嚴肅的期權交易者通過每天學習、逐步進出交易、關注多個指標以及密切關注市場來管理這種風險。</p>

再生元制藥

<p>投資者對再生元製藥（NASDAQ:REGN）表現出樂觀情緒，顯著的期權交易表明潛在價格波動在 400 美元到 800 美元之間。最近的數據揭示交易者的情緒分歧，其中 36% 看漲，36% 看跌。該股票目前交易價格為 760.5 美元，上漲 0.21%，預計將在 16 天后發佈財報。分析師們設定的目標價格平均為 840 美元，其中一位分析師將目標上調至 860 美元。期權交易風險較高，但對於認真投資者來説也提供了更大的盈利潛力</p>

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Regeneron Pharmaceuticals</strong> (NASDAQ: REGN).</p>
<div class="lb-trans"><p>擁有大量資金的投資者對 <strong>再生元製藥</strong> (NASDAQ: REGN) 持樂觀態度。</p>
</div><p>And retail traders should know.</p>
<div class="lb-trans"><p>而散户交易者應該知道這一點。</p>
</div><p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<div class="lb-trans"><p>我們今天注意到這一點，當交易出現在我們在 Benzinga 跟蹤的公開可用期權歷史中時。</p>
</div><p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.</p>
<div class="lb-trans"><p>無論這些是機構還是僅僅是富有的個人，我們都不知道。但當 REGN 發生如此重大的事情時，通常意味着有人知道即將發生什麼。</p>
</div><p>So how do we know what these investors just did?</p>
<div class="lb-trans"><p>那麼我們如何知道這些投資者剛剛做了什麼呢？</p>
</div><p>Today, Benzinga's options scanner spotted 11 uncommon options trades for Regeneron Pharmaceuticals.</p>
<div class="lb-trans"><p>今天，Benzinga 的期權掃描儀發現了 11 筆不尋常的再生元製藥期權交易。</p>
</div><p>This isn't normal.</p>
<div class="lb-trans"><p>這並不正常。</p>
</div><p>The overall sentiment of these big-money traders is split between 36% bullish and 36%, bearish.</p>
<div class="lb-trans"><p>這些大資金交易者的整體情緒在 36% 看漲和 36% 看跌之間分裂。</p>
</div><p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $344,526, and 4 are calls, for a total amount of $458,064.</p>
<div class="lb-trans"><p>在我們發現的所有特殊期權中，7 筆是看跌期權，總金額為 $344,526，4 筆是看漲期權，總金額為 $458,064。</p>
</div><h3>Predicted Price Range</h3>
<div class="lb-trans"><h3>預測價格區間</h3>
</div><p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $400.0 to $800.0 for Regeneron Pharmaceuticals during the past quarter.</p>
<div class="lb-trans"><p>分析這些合約的成交量和未平倉合約，似乎大玩家在過去一個季度內關注再生元製藥的價格區間為 $400.0 到 $800.0。</p>
</div><h3>Volume &amp; Open Interest Development</h3>
<div class="lb-trans"><h3>成交量與未平倉合約發展</h3>
</div><p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Regeneron Pharmaceuticals's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Regeneron Pharmaceuticals's substantial trades, within a strike price spectrum from $400.0 to $800.0 over the preceding 30 days.</p>
<div class="lb-trans"><p>評估成交量和未平倉合約是期權交易中的一個戰略步驟。這些指標揭示了在指定行使價格下，投資者對再生元製藥期權的流動性和興趣。接下來的數據將可視化過去 30 天內與再生元製藥重大交易相關的看漲和看跌期權的成交量和未平倉合約的波動，行使價格範圍為 $400.0 到 $800.0。</p>
</div><h3>Regeneron Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<div class="lb-trans"><h3>再生元製藥期權活動分析：過去 30 天</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768417244_0.png" alt="Options Call Chart" original-src="https://www.benzinga.com/files/images/story/2026/1768417244_0.png"/></p>
<h3>Biggest Options Spotted:</h3>
<div class="lb-trans"><h3>發現的最大期權：</h3>
</div><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$128.3</td>
<td>$122.4</td>
<td>$124.5</td>
<td>$630.00</td>
<td>$311.2K</td>
<td align="right">111</td>
<td align="right">25</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.5</td>
<td>$12.7</td>
<td>$15.5</td>
<td>$775.00</td>
<td>$65.1K</td>
<td align="right">346</td>
<td align="right">42</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.2</td>
<td>$12.3</td>
<td>$15.2</td>
<td>$775.00</td>
<td>$63.8K</td>
<td align="right">346</td>
<td align="right">122</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.4</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$775.00</td>
<td>$61.5K</td>
<td align="right">346</td>
<td align="right">302</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/16/28</td>
<td>$185.0</td>
<td>$179.5</td>
<td>$185.0</td>
<td>$800.00</td>
<td>$55.5K</td>
<td align="right">4</td>
<td align="right">3</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行使價格</strong></th>
<th><strong>總交易價格</strong></th>
<th align="right"><strong>未平倉合約</strong></th>
<th align="right"><strong>成交量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$128.3</td>
<td>$122.4</td>
<td>$124.5</td>
<td>$630.00</td>
<td>$311.2K</td>
<td align="right">111</td>
<td align="right">25</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>掃描</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$15.5</td>
<td>$12.7</td>
<td>$15.5</td>
<td>$775.00</td>
<td>$65.1K</td>
<td align="right">346</td>
<td align="right">42</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>交易</td>
<td>看跌</td>
<td>01/16/26</td>
<td>$15.2</td>
<td>$12.3</td>
<td>$15.2</td>
<td>$775.00</td>
<td>$63.8K</td>
<td align="right">346</td>
<td align="right">122</td>
</tr>
<tr>
<td>REGN</td>
<td>看跌</td>
<td>掃描</td>
<td>看漲</td>
<td>01/16/26</td>
<td>$17.4</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$775.00</td>
<td>$61.5K</td>
<td align="right">346</td>
<td align="right">302</td>
</tr>
<tr>
<td>REGN</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>06/16/28</td>
<td>$185.0</td>
<td>$179.5</td>
<td>$185.0</td>
<td>$800.00</td>
<td>$55.5K</td>
<td align="right">4</td>
<td align="right">3</td>
</tr>
</tbody>
</table>
</div><h3>About Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>關於再生元製藥</h3>
</div><p>Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).</p>
<div class="lb-trans"><p>再生元製藥發現、開發和商業化用於治療眼病、心血管疾病、癌症和炎症的產品。該公司有多個已上市產品，包括用於濕性年齡相關性黃斑變性和其他眼病的低劑量 Eylea 和 Eylea HD；在免疫學領域的 Dupixent；用於降低 LDL 膽固醇的 Praluent；在腫瘤學領域的 Libtayo；以及在類風濕關節炎領域的 Kevzara。再生元還與賽諾菲及其他合作伙伴獨立開發單克隆抗體和雙特異性抗體，並與早期階段的合作伙伴關係引入新技術，包括 RNAi（Alnylam）和基於 Crispr 的基因編輯（Intellia）。</p>
</div><p>In light of the recent options history for Regeneron Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<div class="lb-trans"><p>鑑於再生元製藥最近的期權歷史，現在適合關注該公司本身。我們旨在探討其當前表現。</p>
</div><h3>Present Market Standing of Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>再生元製藥的當前市場狀況</h3>
</div><ul>
<li>Currently trading with a volume of 269,395, the REGN's price is up by 0.21%, now at $760.5.</li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 16 days.</li>
</ul>
<div class="lb-trans"><ul>
<li>目前交易量為 269,395，REGN 的價格上漲 0.21%，現為 $760.5。</li>
<li>RSI 指標顯示該股票目前在超買和超賣之間處於中性狀態。</li>
<li>預計盈利發佈將在 16 天內進行。</li>
</ul>
</div><h3>What The Experts Say On Regeneron Pharmaceuticals</h3>
<div class="lb-trans"><h3>專家對再生元製藥的看法</h3>
</div><p>In the last month, 2 experts released ratings on this stock with an average target price of $840.0.</p>
<div class="lb-trans"><p>在過去一個月中，2 位專家對該股票發佈了評級，平均目標價格為 $840.0。</p>
</div><ul>
<li>An analyst from B of A Securities has elevated its stance to Buy, setting a new price target at $860.</li>
<li>An analyst from Truist Securities has decided to maintain their Buy rating on Regeneron Pharmaceuticals, which currently sits at a price target of $820.</li>
</ul>
<div class="lb-trans"><ul>
<li>一位來自美銀證券的分析師將其評級提升至買入，設定新的目標價格為 $860。</li>
<li>一位來自 Truist Securities 的分析師決定維持對再生元製藥的買入評級，目前目標價格為 $820。</li>
</ul>
</div><p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<div class="lb-trans"><p>期權相比於僅交易股票是一種風險更高的資產，但它們具有更高的利潤潛力。嚴肅的期權交易者通過每天學習、逐步進出交易、關注多個指標以及密切關注市場來管理這種風險。</p>
</div>

這就是大户押注再生元製藥的原因